Category Archives: Fund raising

Fund 101 Launched

Fund 101 Launched

Website Here

If you have an idea for a business and need a bit of cash to get started or you’re running a small business and need up to £500 to buy equipment, promotion flyers, hardware etc, you can apply.

Apply for between £50 and £5000 and once you receive the money, the only thing we ask is you agree to be profiled on the site so we can see how you’re getting on. The money doesn’t have to be paid back; it’s for you to use on your idea or business.

Apply via clicking the button below and outline how much money you need and for what purpose. Make a good case for your idea and then encourage as many people as possible to vote for you. The number of votes required is equal to the amount of funding you’re looking for so to obtain £500 you’ll need to secure 500 virtual votes.

Remember, the Enterprise Nation community will help you spend the dosh! Want to use it to buy a camera to take good pictures of your products? Ask peers about the best deal on the market. Want to spend the money on a Google Adwords campaign but not sure where to start? Watch our video clips that will show you how!

All the support you need is right here so you can access the money you need and keep coming back to pick up tips, access content and pose questions in our friendly forums.


For Assistance with Business Plannign and Fundraising Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

TSB Annoucnes Grant for R&D

TSB Annoucnes Grant for R&D

Full Text Here

A new Technology Strategy Board scheme is offering funding to small and medium-sized enterprises (SMEs) to engage in R&D projects in the strategically important areas of science, engineering and technology, from which successful new products, processes and services could emerge.

Open from 4 April 2011, the Grant for Research and Development (Grant for R&D) scheme will support R&D projects which offer potentially significant rewards and could stimulate UK economic growth. In contrast to the Collaborative R&D programme, Grant for R&D funding is available to single companies.

Three types of grant are available:

  • Proof of market
  • Proof of concept
  • Development of prototype

Any UK SME working in any sector may apply; applications are accepted on a rolling basis for assessment by independent experts.

Grant for R&D replaces the scheme previously offered by regional development agencies. The new scheme will work alongside existing programmes in Scotland, Wales and Northern Ireland.

For Assistance with Preparing Business Plans for Fund Raising Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

£100m New Money Announced for Sciecne

£100m New Money Announced for Science

Full Text Report

BBC has published an article on this extra cash for science

The bulk of the funds (£80m), which come from the bank levy, will be invested in new research centres at Daresbury, Norwich and Cambridge, he said.

The smaller proportion (£20m) would go to projects at Harwell.

These include investments in new space technologies, and in three new instruments at the Isis neutron source.

Isis is a giant machine that can probe the structure of matter. Scientists exploit its insights to advance a host of new technologies from drug design to improved mobile phones.

Also included in the budget was a promise to address regulatory issues that are deemed to impede science-based industries from maximising their performance.

In the life sciences, Mr Osborne announced a new health research regulatory agency that would aim to simplify and speed up the business of running the clinical trials which are essential to the development of new drugs.

For Assistance with Fundraising Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

BUPA Foundation Strategy – Fund

BUPA Foundation Strategy – Fund

Full Text Here

The Bupa Foundation is an independent medical research charity

AIMS

The charitable objects (intentions) expressed above are interpreted in the aims to fund:

  1. Implementation of translational and action orientated research-based solutions, which: :
    • Drive tangible action to prevent or alleviate chronic disease or the adverse elements of ageing; and to promote wellbeing and/or
    • Lead to the sustained uptake of healthy lifestyles and/or
    • Measurably improve public health to a significant degree
  2. AND/OR

  3. Research which leads to the development of such solutions.

OBJECTIVES

The Foundation’s objectives are:
To offer grants to implement research-based solutions, in any of the following areas, which reflect global challenges in public health:

  1. Enabling sustained behaviour changes in physical activity and/or nutrition amongst children, families or in the workplace or educational establishments;
  2. Utilising or developing shared-decision making tools for better patient decisions for use amongst disadvantaged or diverse groups;
  3. Promoting and encouraging healthy ageing through physical activity and other behaviour-based and social solutions for the older age group (65+ years);
  4. Using new technologies to organise and interpret health outcomes data cheaply and effectively – for better design of community health activities and to improve patient decision making.

All projects should develop, apply or test research-based approaches in community settings – with clear intended impacts on public health.

The Bupa Foundation supports high quality medical research through its four programmes:

Programme 1: Research grants (all four objectives above)

In 2011 the first round under the new funding strategy will be held in June 2011. The closing date for this round is 31 March 2011. This may change in future years.

All projects funded under this heading should develop, apply or test research-based approaches in community settings – with clear intended impacts on public health.

The areas for funding as detailed above are not intended to be exclusive of each other.

Research grant applications are open only to clinicians, researchers and health care professionals who are UK residents. Applicants are encouraged to include on their application partnerships with other universities, healthcare organisations, research institutes, charities and community groups

The Foundation will normally consider applications for funding to a maximum of £100,000 per annum for up to three years term. Successful applications are more likely if added value (such as potential for co-funding) is clearly demonstrated.

If funding is required for a longer period a separate application must be made in the third year. Continuing support cannot be guaranteed; any application for further funding will be considered in open competition with other applications submitted on that occasion.

Programme 2: Annual Multi-country Grant

A total grant of up to £600,000 will be awarded to fund one multi-country* initiative of 1 to 3 years duration, under the first funding theme on sustained behaviour changes

“Enabling sustained behaviour changes in physical activity and/or nutrition amongst children, families or in the workplace or educational establishments”"

*This should be defined as a project carried out in at least two of the following countries: United Kingdom, Spain, Australia, New Zealand, the United States or India

It will be advertised on the Bupa Foundation web site and appropriate online journals.

In 2011 it will be judged in September, with a closing date of 20 June 2011.

This time table may change in future years.

Programme 3: Philip Poole-Wilson Seed Corn Fund

A fund of £200,000 per annum to award grants of up to £20,000 each, to fund research into any of the four Research Grant themes.

Each application must be made either by a researcher beginning their research career or if a pilot project by an experienced researcher, must include such a researcher on the team and contribute meaningfully to his/her development and training. High priority will be given to applications from young and/or new researchers who have not previously been funded.

Philip Poole-Wilson Seed Corn fund grant applications are open only to clinicians, researchers and health care professionals who are UK residents Applicants are encouraged to include on their application partnerships with other universities, healthcare organisations, research institutes, charities and community groups

This grant round will be held in November each year, with a closing date of 31 July.

Programme 4: Annual Prizes

£60,000 will be allocated for completed research and/or development that has been conducted over the past 3 years into each of the four Research themes; -

  1. Healthy Lives Prize
  2. Enabling sustained behaviour changes in physical activity and/or nutrition amongst children, families or in the workplace

  3. Patients as Partners Prize
  4. Utilising or developing shared-decision making tools for better patient decisions for use amongst disadvantaged or diverse groups;

  5. Vitality for Life Prize
  6. Promoting and encouraging healthy ageing through physical activity and other behaviour-based and social solutions for the older age groups (65+ years)

  7. Technology for Healthy Outcomes Prize
  8. Using new technologies to organise and interpret health outcomes data cheaply and effectively for better design of community health activities and improved patient decision making.

Foundation Prizes will focus on recognition of excellent work by aspiring and promising new researchers in the early phases of their career.

Foundation Prizes are advertised in January/February each year, with a closing date in early July. Full details of Awards entry criteria and the application process can be found at: http://www.bupafoundation.co.uk/asp/awards/eligibility.asp.

The Chairman and Board of Governors of the Bupa Foundation reserve the right to amend and/or add to Programme details as they consider appropriate, at any future date.

For Assistance with Grant Funding and Business Planning Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Free pitching events, managed by Angel News

Free pitching events, managed by Angel News

Colleagues – I thought this may be of interest to you?

AngelNews, an online news service for entrepreneurs and investors is inviting you to pitch at its launch events of Pitching for Management in Leeds and Sheffield at NO CHARGE.

These events allow entrepreneurial people like you to pitch to rooms full of senior executives to join your teams in exchange for sweat equity, commission and/or salary.  Pitching for Management has been running in London since January 2009 and has started rolling out throughout the UK.

Typically audience members have worked with fast-growth companies in the past and have a wealth of experience in roles ranging from sales, marketing and finance directors, to mentors, non-executives directors and CEO’s.

So if you need a sales director who will help you build revenue, an FD who will look after the money side of things or even a chairman or NED who will help you fulfill its overall potential, you can come and pitch for them for free.  (Whatever your stage of business)

Pitching for Management offers great exposure to a high-calibre audience and hopefully you will find that perfect person you’ve been looking for.

If this sounds of interest to you, call Michelle Williams of AngelNews on 01761 452248 or email michelle@angelnews.co.uk.   She will be happy to talk through the concept with you.

Pitching for Management is taking place in Leeds on 31st March and Sheffield on 12th April.

We are holding a similar event in Manchester on 30th March.

For Assistance with Business Planning and Fund Raising Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Deputy PM Announces New Round of the Regional Growth Fund

Deputy PM Announces New Round of the Regional Growth Fund

Deputy Prime Minister Nick Clegg has announced that a second bidding round of the Regional Growth Fund will open on 12 April 2011.

The Government announced in the 2010 Budget, that it would commit itself to create a Regional Growth Fund (RGF). Launched as part of the publication of the Coalition Government’s Local Growth: Realising Every Place’s Potential White Paper, the Fund completed its first round earlier this year.

The RGF is a discretionary £1.4 billion Fund that will operate for three years between 2011 and 2014 to achieve its two main objectives of:

  • stimulating enterprise by providing support for projects and programmes with significant potential for creating long-term private sector led economic growth and employment; and
  • helping those areas and communities that are currently dependent on the public sector make the transition to sustainable private sector-led growth and prosperity.

The Fund subsequently encourages private sector enterprise, including social enterprise, to create opportunities for people and places to adjust to reductions in public spending, and enable private sector investors, business, the public sector and communities to come together with an overall strategy for their area.

Bids for funding from private bodies and public-private partnerships across England on a challenge basis are welcomed; however, the minimum amount of grant that can be applied for is £1 million.

Ministers are currently considering increasing the amount of funding available in the first round of bidding to the Regional Growth Fund as the Government prepares to announce which projects will benefit.

Deputy Prime Minister Nick Clegg made the announcement of the second round during a summit for local enterprise partnerships in Coventry. He said the successful first round bids to the Fund would be made public “shortly” and that the number of high quality bids received had led the Government to consider whether to increase the share of the £1.4 billion overall Fund available in the initial round.

Round two will open to applications on 12 April 2011.

Further details of the Fund are available online at the BIS website (opens in new window).

For Assistance with Fund Raising and Commercialisation Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

FDA Announces Grant Funding for Safety and Effectivenss of Orphan Products Rsearch Project Grant (R01)

FDA Announces Grant Funding for Safety and Effectiveness of Orphan Products Research Project Grant (R01)

Full Text Here

The Food and Drug Administration (FDA) is announcing the availability of grant funds for the support of FDA’s Office of Orphan Products Development (OPD) grant program. The goal of FDA’s OPD grant  program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the proposed product will be superior to the existing therapy. FDA  provides grants for clinical studies on safety and/or effectiveness that will either result in, or substantially contribute to, market approval of these products. Applicants must include in the  application’s Background and Significance section documentation to support the estimated prevalence of the orphan disease or condition (or in the case of a vaccine or diagnostic, information to support the  estimates of how many people will be administered the diagnostic or vaccine annually) and an explanation of how the proposed study will either help support product approval or provide essential data needed
for product development.

For an Orphan Regulatory Expert EU or USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Michael J. Fox Foundation Commits up to US$12 Million for Targeted Parkinson’s Therapeutic Development in 2011

Michael J. Fox Foundation Commits up to US$12 Million for Targeted Parkinson’s Therapeutic Development in 2011

Full Text Here

Funding is open to academic and industry researchers through the Foundation’s Pipeline Programs, which consist of three annually recurring initiatives, known collectively as The Edmond J. Safra Core Programs for PD Research, as well as the industry-exclusive Therapeutics Development Initiative. The Foundation seeks investigator-initiated proposals focused on the following critical points along the translational pathway to new therapies for Parkinson’s disease:

  • Testing Novel Hypotheses: Quick support for high-risk, high-reward projects with little to no existing preliminary data, but potential to significantly impact our understanding or treatment of PD.
  • Validating Novel Targets: Support for work demonstrating whether modulation of a novel biological target has impact in a PD-relevant pre-clinical model — an essential step to the development of potential targeted therapies.
  • Catalyzing and Expanding Preclinical Development: Industry-exclusive support for preclinical development of Parkinson’s disease therapies with potential to fundamentally alter disease course and/or improve treatment of symptoms above and beyond current standards of care.
  • Clinically Testing Novel Therapies: Support for clinical testing of promising PD therapies that may significantly and fundamentally improve treatment of PD.

“The Pipeline Programs are a core element of our Foundation’s efforts to drive research that will speed therapeutic development at historically under-funded points on the pipeline,” said Todd Sherer, the Foundation’s acting CEO. “The programs are part of MJFF’s progressive work to keep the most promising and significant projects moving forward toward notably improving quality of life for patients now and in the future.”

Brief program descriptions follow. Full details are available at www.michaeljfox.org/research.

For Business Planning Services Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Market Report on Life Sciences and Healthcare Sector Forecasts

Market Report on Life Sciences and Healthcare Sector Forecasts

Published by Rodman and Renshaw and EpstineBeckerGreen full Text Here

Based on interviews with over 75 healthcare investors in the US, this report offers valuable insight into emerging trends in investment activity, as well as a detailed forecast for specific subsectors, including biotechnology and pharmaceuticals; medical devices; healthcare providers and payors; and healthcare services.

Respondents to this survey unanimously agree that healthcare M&A activity will either increase or remain at its current level over the next 12 months. The biotechnology and pharmaceuticals subsector and the healthcare services subsector are particularly likely to witness a significant increase in M&A during this time, according to 87% and 83% of respondents, respectively.

Investment patterns are likely to vary according to industry over the next 12 months. Strategic buyers are likely to be most active in the biotechnology and pharmaceuticals subsector, following on a recent wave of large-cap deals including the US$68bn Pfizer-Wyeth merger and the US$44bn Roche-Genentech merger. Financial buyers, on the other hand, are likely to focus their attention on the healthcare services space, where recent private equity buyouts include TPG Capital’s US$5.3bn acquisition of IMS Health.

Click Here for Business Planning Services

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

FDA, the US Drug Regulator, Reminder of Tropical Disease Priority Review Vouchers

FDA, the US Drug Regulator, Reminder of Tropical DIsease Priority Review Vouchers

This guidance provides information on the implementation of section 1102 of the Food and Drug Administration Amendments Act of 2007 (FDAAA), which adds new section 524 to the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360n). Section 524 authorizes FDA to award priority review vouchers to sponsors of certain tropical disease product applications that meet the criteria specified by the Act. A priority review voucher may be used by the sponsor who obtains it or another sponsor to obtain a priority review for a different application. A priority review voucher may be transferred from the sponsor who obtains it to another sponsor.

These vouchers are valued at between US$50 and US$300 million, and there is grant money available to fund development it is a great way of generating large anounts of value whilst saving lives.

For Business Planning Services Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

ida consultants freestrategyconsultation 515x64 FDA, the US Drug Regulator, Reminder of Tropical Disease Priority Review Vouchers

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

ida 100programme 515x64 LowRes FDA, the US Drug Regulator, Reminder of Tropical Disease Priority Review Vouchers

New Oxford Fund to Bridge Innovation Gap

New Oxford Fund to Bridge Innovation Gap

A new Fund launched today by Oxford University will enable donors to support proof of concept and prototyping work to turn more research ideas into commercially-viable technologies, products and services.

The Oxford Invention Fund, which will be managed by Oxford University’s technology transfer company Isis Innovation, is part of Oxford Thinking, the Campaign to raise a minimum of £1.25bn for the collegiate University.

It is widely recognised that there is an ‘innovation gap’ between the early stages of an invention or idea and the point when it is mature enough to be commercialised through a license or spin-out company. The new initiative aims to raise up to £5m to create a self-sustaining fund to help develop Oxford inventions to the point when they can attract commercial investment.

‘Many university-based inventions lack well-developed product prototypes and vital experimental data to help them succeed, and obtaining funds for such work from venture capital providers or research funders is still a problem,’ said Tom Hockaday, Managing Director of Isis Innovation. ‘The aim of this Fund is to support the work needed to make even more Oxford inventions attractive propositions for licensing or investment.’

‘The Oxford Invention Fund provides the opportunity for donors to the University to see their donations used to support innovation and enterprise in Oxford, and to see a return to the University from successful new business ventures,’ said Bernard Taylor, Chairman of Isis Innovation.

Isis Innovation has a long track-record of success in exploiting research discoveries and ideas from Oxford University. In the last ten years Isis has set up 54 new technology spin-out companies, over 90% of which are still in business, and concluded 500 technology licensing transactions. Isis currently manages over 750 technology projects and files on average more than one new patent application each week.

Isis Innovation has managed the highly successful Oxford University Challenge Seed Fund (UCSF) which, since it was first launched in 1999, has awarded £5.7m, financing 102 projects and prompting the formation of 31 spin-out companies and the completion of 51 commercial deals.

The Oxford Invention Fund is modelled after the UCSF, with returns from its investments re-invested in further projects so that it can continue to support innovation at Oxford for many years to come. It is hoped that one day money generated from the Fund could be used to subsidise scholarships and bursaries to help the next generation of inventors and scientists.

For Business Planning and Fund Raising Services Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

ida consultants freestrategyconsultation 515x64 New Oxford Fund to Bridge Innovation Gap

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

ida 100programme 515x64 LowRes New Oxford Fund to Bridge Innovation Gap

UK Government to set up Regional Growth Fund

UK Government to set up Regional Growth Fund.

Plans have been announced to establish a growth fund worth £1 billion to support business and economic development in those English regions likely to be hit by public spending cuts.

The fund is due to operate as from next year until 2013 in an effort to smooth the transition to private-sector led growth.

It will play a part in replacing the nine English Regional Development Agencies which are to be phased out by March 2012. A number of RDA roles will be transferred to smaller local enterprise partnerships.

Making the announcement, Nick Clegg, the Deputy Prime Minister, said: “While we sort out the nation’s finances we can also help to foster a thriving and more balanced economy so that no region or community gets left behind.

“The Regional Growth Fund will create the conditions for growth and enterprise in the regions by stimulating investment and create sustainable private sector jobs.

In a joint letter sent to councils and business leaders, Business Secretary, Vince Cable and Communities Secretary, Eric Pickles have asked them to consider forming new local enterprise partnerships that can provide strategic leadership in their local areas and create the right environment for business success.

Vince Cable said: “We are determined to rebalance the economy towards the private sector, so it’s important we create a more effective structure to drive economic growth and development across the country.

“We want a structure that reflects the genuine interests and commitment of enterprise, local councils and other stakeholders like universities and colleges. Local enterprise partnerships will provide that vision and then take on the task of renewing local economies and tackling local barriers to growth.”

Local enterprise partnerships will tackle issues including planning and housing, local transport and infrastructure, employment, enterprise and supporting business start-ups.

The statement, however, made clear that some roles currently carried out by the RDAs will be switched to Whitehall, such as inward investment, sector leadership, business support, innovation and access to finance.

Further details of the Regional Growth Fund, and the creation of LEPs, will be set out in the forthcoming White Paper on local and regional growth.

Responding to the announcement, David Frost, the director general of the British Chambers of Commerce (BCC), said: “Whatever new structures emerge, it is clear that local business leaders need to play a central role in defining every area’s economic future.

“Given the long-standing economic challenges that face so many parts of the country, business must be assured that private sector growth, job creation, and balanced local economies are LEPs’ overriding priorities.”

But Mr Frost warned: “While business will wait to see detailed plans on the proposed Regional Growth Fund, what’s clear from the outset is that the Fund will have significantly less resources to support business growth than previous arrangements.

“While business has been fully supportive of the government’s drive to reduce the UK’s deficit, we believe that investment in the business environment must remain a key priority – especially in those areas of the country that have not seen significant private-sector growth.”

Click Here for Business Planning Services

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

ida consultants freestrategyconsultation 515x64 UK Government to set up Regional Growth Fund

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

ida 100programme 515x64 LowRes UK Government to set up Regional Growth Fund

BIA – Fund Map Useful Tool for Finding Funding For Your Technology Development

BIA – Fund Map Useful Tool for Finding Funding For Your Technology Development

Site Here

The BIA Fundmap provides easy navigation to the grants and funding available to businesses in the UK bioscience sector.

Click Here for Drug Development Services

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

ida consultants freestrategyconsultation 515x64 BIA   Fund Map Useful Tool for Finding Funding For Your Technology Development

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

ida 100programme 515x64 LowRes BIA   Fund Map Useful Tool for Finding Funding For Your Technology Development

METRC – Short Term Project Funding Call

METRC – Short Term Project Funding Call

Short Term Project Funding is designed to support small research projects to explore the feasibility of innovative new products and processes.

In the first stage, funds of up to £3,000 are available to support collaborative projects between industry and METRC’s academic members.

Second stage funds of £7,000 are available for the most successful projects providing there is a match from the industrial partner.

For more information please go to our website www.molecularengineering.co.uk/funding_calls.php

If you would like to discuss a project idea please contact one of the METRC team:

METRC@sheffield.ac.uk

+44 (0)114 222 9450

About METRC

METRC is a virtual lab pooling expertise from leading research centres at Universities across the

North of England. Our focus is on soft nanotechnology and its applications in industry. Our target

markets include home and personal care, medicine and healthcare, and energy.

CMC Consulting Services

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

ida consultants freestrategyconsultation 515x64 METRC   Short Term Project Funding Call

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

ida 100programme 515x64 LowRes METRC   Short Term Project Funding Call

New 10% Tax Rate for Patent Income

New 10% Tax Rate for Patent Income

Taken From RMS Bentley Jennison Pre-Budget Report Review

A new tax rate of 10% for income derived from patients s to be introduced, compared to the current corporation tax rte of 28%. The details reveal that the new regime is set to apply to patents granted after April 2013, i.e. in more than 3 years time, with the legislation only to be included in the Finance Bill 2011, following consultation on the design of the scheme. Whilst this measure may appear to be aimed far into the future, the development of patented products can take time and the intention is clearly to encourage future R&D in the UK.

If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free.

As you know this website is a great resource for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.

First name

E-mail address

This guideline ap
recombinant vaccines for the prevention and treatment of infectious disease, and provides guidance on quality, non-clinical and clinical aspects.
ida consultants freestrategyconsultation 515x64 New 10% Tax Rate for Patent Income

ida 100programme 515x64 LowRes New 10% Tax Rate for Patent Income

Turn your Business Into an Investor Magnet

How to Write a Business Plan – Free E-Course

Get the secrets that turns your project into an investment magnet, 100% of our clients raise the finance they need to take their projects to the next stage, we will share these secrets with you. – Sign up for Free

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

New Fund Available for Industry / Uni Tie ups

3rd Call for applications

i4i Funding Streams 3a (FPD3a) and 3b (FPD3b)

The NIHR’s Invention for Innovation (i4i) programme would like to invite submissions of applications to funding streams 3a and 3b (FPD3a and FPD3b).

Stream 3a applications must include collaboration between at least one industry and one research (academic or clinical) partner aiming to determine the commercial viability of a proposed device or technology, with the development of a robust route to market and a strong, appropriate consortia serving as key deliverables.  Primarily expected to be the first stage of a full collaborative applied research project, total project costs can be no more than £100K in total, of which 75% funding is available.

Stream 3b applications should build on the results of a completed assessment of feasibility and must also have collaboration between at least one industry and one research partner (academic or clinical). This will provide further evidence of the capability to deliver improved healthcare outcomes and commercial opportunity, delivering an advanced prototype along with plans for commercial and intellectual property exploitation. Lasting no longer than 3 years, successful projects will be funded to a maximum of 50% of the total project costs, with £100K-£300K per year in funding available.

All applications must show innovation and must have relevance, impact and potential to contribute to future health gain for patients and the general population.  This programme is open to research providers in the academic, NHS communities and industry across the UK.

For further information on eligibility and to submit an application please visit http://www.nihr-ccf.org.uk/site/programmes/i4i/ or email any questions that you may have to i4i.enquiries@quotec.co.uk.

Applications must be submitted via the NIHR CCF website no later than 5.00pm on Friday 29th January 2010. Applicants will be notified of the outcome of their application by late March 2010.

If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Free Regulatory Watch Service

As you know this website is a great resource for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.

First name

E-mail address

This guideline ap
recombinant vaccines for the prevention and treatment of infectious disease, and provides guidance on quality, non-clinical and clinical aspects.
ida consultants freestrategyconsultation 515x64 New Fund Available for Industry / Uni Tie ups

ida 100programme 515x64 LowRes New Fund Available for Industry / Uni Tie ups

Turn your Business Into an Investor Magnet

How to Write a Business Plan – Free E-Course

Get the secrets that turns your project into an investment magnet, 100% of our clients raise the finance they need to take their projects to the next stage, we will share these secrets with you. – Sign up for Free

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

METRC Announce Short Term Project Funding

METRC Announce Short Term Project Funding £3000 going to £7000.

Short Term Project Funding is designed to support small research projects to explore the feasibility of innovative new products and processes. In the first stage, funds of up to £3,000 are available to support collaborative projects between METRC’s academic members and industry partners. The funding can be used flexibly at the METRC academic  institutions on a range of activities such as project consumables, paying for researchers or some limited consultancy work. For the most successful projects, funding can be extended into a second stage worth up to an additional £7,000 providing there is a matching contribution from an industrial partner.

he call will open on 16th October 2009 and funding will be available on a first-come first-served basis. We will be accepting applications for stage 2 funding from 1st January 2010 and there is funding available to support up to 10 stage 2 projects. We expect that a second tranche of Short Term Project Funding will be made available during 2010.

The Contacts Are:

Richard France – r.m.france@sheffield.ac.uk, 0114 222 9563
Simon Butler – simon.butler@sheffield.ac.uk, 0114 222 9450
Sam Whitehouse – S.P.Whitehouse@sheffield.ac.uk, 0114 222 9493

If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

ida 100programme 515x64 LowRes METRC Announce Short Term Project Funding

Turn your Business Into an Investor Magnet

How to Write a Business Plan – Free E-Course

Get the secrets that turns your project into an investment magnet, 100% of our clients raise the finance they need to take their projects to the next stage, we will share these secrets with you. – Sign up for Free

Grow your Expertise for Free

As you know this website is a great resource for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.

First name

E-mail address

This guideline ap
recombinant vaccines for the prevention and treatment of infectious disease, and provides guidance on quality, non-clinical and clinical aspects.
ida consultants freestrategyconsultation 515x64 METRC Announce Short Term Project Funding

Drug/Biotech Development Fund, UK government announces GB£150m fund

Drug/Biotech Development Funding, UK Government Announces a GB£150 million fund.

UK government press release: 29th June 2009

The Prime Minister has today announced the creation of the UK Innovation Investment Fund to invest in technology-based businesses with high growth potential. The new fund will focus on investing in growing small businesses, start-ups and spin-outs, in digital and life sciences, clean technology and advanced manufacturing.

The Department for Business, Innovation and Skills, with the Department of Energy and Climate Change and the Department of Health, will invest £150 million alongside private sector investment on an equal basis known as pari-passu.

It is the Government’s belief that this could leverage enough private investment to build a fund of up to £1 billion over the next 10 years. The UK Innovation Investment Fund forms part of the Government’s strategy for Building Britain’s Future.

The UK Innovation Investment Fund will operate on a Fund of Funds structure which means it will not invest directly in companies, but rather invest in a small number of specialist technology funds that have the expertise and track record to invest directly in companies. The fund will provide a cost effective solution that provides a market return to both private sector investors and HM Government.

If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

ida consultants freestrategyconsultation 515x64 Drug/Biotech Development Fund, UK government announces GB£150m fund

Grow your Expertise for Free

As you know this website is a great resource for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.

This guideline ap
recombinant vaccines for the prevention and treatment of infectious disease, and provides guidance on quality, non-clinical and clinical aspects.

Development Funding – New £15million Venture Capital Fund in North West

New Funding Opportunity for Biotech and Pharma in the North West

The Northwest Regional Development Agency (NWDA), with support from the European Regional Development Fund (ERDF), has announced a £15m transitional venture capital (VC) & loan fund for businesses in the region, at the Business Finance 09 seminar in Manchester today (Monday 29th June).

The new fund, providing VC and loan funding has been created to ensure there is no gap in public finance support for businesses in the Northwest, whilst details on the new long term Northwest Venture Capital & Loan Fund are completed.

Venture Capital & Loan funding (VCLF) is a combination of loan, equity and mezzanine funding to support business growth. Loans range from £50,000 to £250,000 with Equity and Mezzanine finance available up to £2m.

For more information on Finance for Business please visit www.nwdabusinessfinance.co.uk

If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

ida consultants freestrategyconsultation 515x64 Development Funding   New £15million Venture Capital Fund in North West

Grow your Expertise for Free

As you know this website is a great resource for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.

This guideline ap
recombinant vaccines for the prevention and treatment of infectious disease, and provides guidance on quality, non-clinical and clinical aspects.

Drug Development – Logic Models of Pathway Biology

As part of our drug development consultancy we often investigate alternative indications for technologies, we progress through the therapeutic pathway and think about where this drug/biological may have an effect be that positive or negative. Having just read an interesting article in Drug Discovery Today (Vol 13 (9/10) May 2008) by Watterson, Marshall and Ghazal. The article titles “logic models of pathway biology” looks at complex living systems and how logic can be used to determine how a drug will interact with the complex biologic pathways.

They describe computational models that comb the pathways for the upstream interactions that control downstream behaviour, allowing them to identify lead candidates for therapeutic treatments. They take the kind of literature based approach we follow to the next level studying proteins, genes and gene products.

Biological pathways can comprise one or more of the following:

  • Metabolic pathways
  • Molecular interactions
  • Gene regulatory networks
  • Signalling pathways

Whilst the researchers hear focus on Boolean Logic and computer modeling we hold that a good review of possible effects and pathways can be tackled using literature searches and scientific hypothesis. I would propose that any drug or biological agent should undergo a similar scrutiny to find new opportunities and highlight potential issues.

Where we look at biological systems they magnify the process, the target the same, an understanding of how a system operates.  It is an interesting article that is well worth reading.

If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

ida consultants freestrategyconsultation 515x64 Drug Development   Logic Models of Pathway Biology

Grow your Expertise for Free

As you know this website is a great resource for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.

This guideline ap
recombinant vaccines for the prevention and treatment of infectious disease, and provides guidance on quality, non-clinical and clinical aspects.